Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nektar Therapeutics ( (NKTR) ) has shared an announcement.
On April 3, 2025, Nektar Therapeutics was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Rule, as its stock price had fallen below $1.00 for 30 consecutive trading days. However, by June 23, 2025, the company regained compliance by maintaining a stock price of at least $1.00 for 10 consecutive business days, ensuring its continued listing on The Nasdaq Capital Market.
The most recent analyst rating on (NKTR) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
The overall stock score reflects the significant financial challenges faced by Nektar Therapeutics, despite strong technical analysis and positive corporate events. The company’s ongoing losses and valuation difficulties weigh heavily, although recent trial successes and strong technical momentum provide a positive outlook. The earnings call provides a mixed signal with financial strength but litigation concerns.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics operates in the biopharmaceutical industry, focusing on the development of innovative therapies for patients with unmet medical needs.
Average Trading Volume: 1,361,742
Technical Sentiment Signal: Buy
Current Market Cap: $361.3M
For an in-depth examination of NKTR stock, go to TipRanks’ Overview page.